Pi Health is committed to
empowering life sciences companies
to develop medicines faster and
reach diverse patient populations

Geoff Kim, MD

Co-Founder & CEO

Dr. Geoffrey Kim is the co-founder and Chief Executive Officer of Pi Health, a healthcare technology company launched in 2021 whose mission is to drive innovation to enable patients all over the world to have equal access to the highest quality of care and research. He has over 25 years of experience in oncology drug development, regulation, and precision medicine.

As Vice President of Applied Innovation at BeiGene, Geoff established an innovative team focused on increasing patient access to clinical trials and novel cancer therapies. His group pioneered methodologies to integrate diverse datasets and drive pipeline advancement through data analysis and strategic development, while simultaneously laying the groundwork for the establishment of Pi Health through the invention of the FICS technology platform.

Prior to his role at BeiGene, Geoff served as Vice President of Oncology Regulatory Science and Strategy at AstraZeneca. He led the regulatory function and shaped regulatory strategies for oncology treatments in a complex, evolving landscape, leading to the approvals of acalabrutinib in CLL and trastuzumab-deruxtecan in metastatic breast cancer. Previously, as Vice President of Strategic Combinations, he defined development and commercialization approaches for immuno-oncology combinations, external partnerships, and women’s cancers, including the strategic oversight of IO-based combination such as the combination of durvalumab and olaparib in multiple solid tumors.

Earlier in his career, Geoff played a pivotal role in oncology regulation at the U.S. Food and Drug Administration (FDA). As Deputy Director of the Oncology Center of Excellence, he helped launched the OCE under the provisions of the 21st Century Cures Act and laid the framework for the unified review of drugs, devices, and biologics that are intended to cure, treat, and prevent cancer. Geoff was also director of the Division of Oncology Products 1 in the Office of Hematology Oncology Products, where he oversaw the evaluation and regulation of oncology drug products for breast, genitourinary and gynecologic cancers and approved practice changing medicines such as CDK4/6 inhibitors for breast cancers, PARP inhibitors for ovarian cancers, and immunotherapy for genitourinary malignancies. He was also involved with numerous cross-functional working groups, developing policies pertaining to in-vitro companion diagnostics, combination products, and therapy dose optimization strategies for cancer medicines.

Dr. Kim completed his medical oncology fellowship at the National Cancer Institute (NCI) where he was active in both laboratory and clinical research in molecular signaling and ovarian cancer. He received his medical degree from New York Medical College and completed his residency in internal medicine at the Montefiore Medical Center.

Bobby Reddy, MD

Co-Founder & CEO

Dr. Bobby Reddy, MD is the Chief Operating Officer and Co-Founder of Pi Health. At Pi Health, he leads global operations, business development, and commercial activities with the mission of driving equal access to innovative medicines and clinical trials for patients around the world. Previously, he served in leadership positions at BeiGene and AstraZeneca. At BeiGene, he was Executive Director of Applied Innovation, a technology incubator in the Office of the CEO, which developed novel technologies to improve R&D and commercial capabilities. In this role, Dr. Reddy was the co-inventor of multiple patented technology applications which have successfully undergone enterprise adoption. He also built and managed multidisciplinary, global teams who led strategy, business development, global operations, and legal activities to drive development, implementation and growth of incubated technologies and companies. At AstraZeneca, Dr. Reddy was Head of Oncology Regulatory Science and Innovation, where he was a member of the global Oncology Regulatory Science and Strategy leadership team.

Previous to his roles in pharma and biotech, Dr. Reddy was faculty of Harvard Medical School and a physician scientist and clinical dermatologist at Massachusetts General Hospital. His research focused on investigating the role of genetic and immunologic factors in melanoma development and progression, along with the development of novel therapeutic strategies. He is also an alumnus of the Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program, through which he conducted research at the National Cancer Institute. He completed an Internal Medicine internship at Brigham and Women’s Hospital, during which he was given the Dunne Award for Humanism in Medicine by Harvard Medical School. He subsequently completed a Dermatology residency at Columbia University Medical Center, where he served as a Chief Resident during his final year of training. After residency, he completed a Melanoma Fellowship at Massachusetts General Hospital/Harvard Medical School. He obtained his M.D. with Alpha Omega Alpha honors from Rutgers–New Jersey Medical School. Dr. Reddy is a board-certified dermatologist and maintains an active clinical practice caring for patients at Massachusetts General Hospital, where he also teaches and mentors medical students and trainees.

Rajuli Lall

CPO (Chief Product Officer & Head of Clinical Research)

Rajuli Lall is a visionary leader and the Chief Product Officer and Head of Clinical Research at Pi Health. Her strategic acumen and extensive expertise in clinical development and operations have made her an instrumental force within the organization and the development of the FICS® software platform. With an illustrious career that spans leading pharmaceutical companies, innovative biotech firms, and academia, Rajuli has carved a niche in the realm of oncology drug and product development.

She is recognized for her adeptness in steering global clinical trials, managing cohesive cross-functional teams, and providing meticulous oversight of clinical operations. As a research scientist, Rajuli specialized in the study of Molecular Medicine and Radiation Biophysics, with a particular emphasis on the biological underpinnings of cancer. Her contributions are a testament to her commitment to advancing medical research and innovation.

Rajuli Lall's profound knowledge and pioneering spirit are central to Pi Health's mission, enabling the company to transform clinical trials and healthcare technology across the globe.

Adrian Myers

CTO

Adrian Myers, as the Chief Technology Officer of Pi Health since January 2023, is a key figure in advancing the company's mission in health technology and clinical research. Based in Fulton, Maryland, his expertise is pivotal in Pi Health's commitment to transforming global access to innovative medicines and clinical trials.

Concurrently with his role at Pi Health, Myers has been the Senior Director of Applied Innovation Technology at BeiGene since August 2022. His work focuses on identifying and implementing novel technologies to reduce costs and improve data quality in oncology clinical trials and drug development.

Prior to joining Pi Health and BeiGene, Myers was a Specialist Leader at Deloitte Consulting in Arlington, Virginia. He served as the technical lead for FutureScape, an AI analytics asset built around novel technologies that he authored. These include ASim, a distributed application framework and modeling environment for agent-based simulations, which has since been patented. His skills in modeling and simulation, high-performance computing, and team leadership were pivotal in this role.

Myers also served as the Principal Architect for Gaming on the Google Cloud Platform at Google for a brief period in 2021. His work at Google, based in Irvine, California, involved high-level architectural responsibilities in the gaming sector.

Before Google, he was again with BeiGene from November 2019 to January 2021 as the Senior Director of Applied Innovation Technology. Here, he heavily focused on the development of the FICS system, a large health data application aimed at reducing drug development clinical trial costs.

His journey also includes a significant tenure at the FDA as an Entrepreneur in Residence from March 2016 to February 2018. Here, he utilized his data science skills in cancer data aggregation and analysis, contributing to significant internal and external health data projects.

Adrian Myers' career trajectory showcases his exceptional ability to blend technology with healthcare, making him an integral part of Pi Health's leadership in driving technological innovation in clinical research.

Chao Liu, PHD

CFO

Dr. Chao Liu, as the Chief Financial Officer and a Founding Member of Pi Health since September 2021, plays a critical role in steering the company's strategic financial direction. Based in the Washington DC-Baltimore area, his expertise is central to Pi Health's mission of revolutionizing clinical research globally through cutting-edge technology.

Before his current role at Pi Health, Dr. Liu served as Senior Director of Applied Innovation Quantitative Solutions at BeiGene. His impactful work included creating and delivering tailored analytic solutions, performing market assessments and real-time valuations, implementing innovative technology in oncology therapeutic development.

Prior to BeiGene, Liu was part of the Food and Drug Administration (FDA) from September 2014 to December 2019. He started as a Reviewer in Clinical Pharmacology/Pharmacometrics and later became a Team Leader in the same division. His focus areas included oncology, hematology, infectious diseases, cardiovascular, and renal diseases. At the FDA, Dr. Liu was responsible for overseeing high-quality and timely reviews of NDA and IND submissions, supervising and mentoring review teams, and leading research projects in regulatory sciences. In addition, he led or participated in the drafting and publication of multiple FDA guidance for industry.

Dr. Liu's journey through these diverse roles reflects a deep commitment to advancing the integration of financial strategy with healthcare innovation. His expertise in quantitative analysis and regulatory sciences, coupled with his financial acumen, positions him as a key driver in Pi Health's pursuit of transforming clinical research infrastructure on a global scale.

Brenton Fargnoli, MD

Board Director

General Partner, AlleyCorp

Brenton is a General Partner leading the Healthcare team at AlleyCorp, where he leads investments and incubations across digital health with a particular focus on value-based care and physician entrepreneurship. Prior to AlleyCorp, Brenton was an executive at Flatiron Health (acquired by Roche), where he built its value-based care business from the ground up and was instrumental in the launch of OneOncology (acquired by AmerisourceBergen). He worked previously at J.P. Morgan and Blue Cross & Blue Shield. An avid supporter of the New York healthcare ecosystem, Brenton serves on the boards of Fund for Public Health NYC and Digital Health New York.

Board-certified in Internal Medicine, Brenton previously practiced at Memorial Sloan Kettering and completed residency at Harvard’s Brigham and Women’s Hospital. He graduated summa cum laude from the University of Pennsylvania, earning an MD from the University of Pennsylvania School of Medicine and an MBA in Healthcare Management from the Wharton School.

Vishal Vasishth

Board Observer

Co-Founder and Managing Director, Obvious Ventures

Vishal invests in values-driven founders and companies that dramatically improve healthcare outcomes, create more human-centered financial systems, and reimagine consumer services from the ground up.

He leads Obvious' investments in full-stack healthcare with Virta, Galileo, and Devoted Health; financial technology startups such as Hedvig, One, Corvus, and Openly; and purpose-led consumer services like Good Eggs and Block Renovation.

Before co-founding Obvious, Vishal was the founding partner of Indian-based fund SONG Investment Advisors. He also served as a senior executive at Steve Case’s Revolution, LLC. Prior to his career as an investor, Vishal spent a decade at outdoor gear and apparel retailer Patagonia, in roles ranging from product manager to Chief Strategy Officer. He was selected as a Henry Crown Fellow of the Aspen Institute and a Next Generation Fellow of the American Assembly, both recognizing value-based leadership. Vishal earned a B. Tech degree in India, an MS from North Carolina State University, and an MBA from UCLA's Anderson School of Management.

Rohan Ganesh

Board Director

Partner, Obvious Ventures

Rohan invests in mission-driven team building companies that transform pharma operations and catalyze biological breakthroughs.

Prior to joining Obvious, he led venture investments in biotech, diagnostics, and healthcare technology companies at Verily Life Sciences, a Google spinout, and at Northpond Ventures, a life-sciences focused venture firm. He started his career in product management roles at CompuGroup Medical, building electronic medical records, and at Verily, productizing neural networks for diagnostic applications.

Rohan studied Biological Sciences at the University of Oxford and earned an MBA from Harvard Business School.

Michael Schoen

Board Director

Strategic Advisor and Special Assistant to CEO, BeiGene

Michael joined BeiGene in 2017 and serves as Strategic Advisor and Special Assistant to the CEO. In addition, Michael oversees Global IT, Global Workplace Services, and U.S. Government Affairs. Prior to that he was Chief of Staff and Special Advisor to the CEO as well as SVP, Business Operations, overseeing Global HR, Global IT, Global Workplace Services, and U.S. Corporate Communications. In all those roles Michael works closely with John V. Oyler and other senior management to help direct BeiGene's operations and work to meet its goals.

Before joining BeiGene, Michael was a Managing Director and the Regional Head of Latin America and Caribbean Debt Capital Markets and Derivative Solutions for Scotiabank, based in New York. In this capacity, he was responsible for overseeing the origination and execution of all debt and derivative transactions from and within the region. Michael joined Scotiabank in early 2013 after twelve years in a similar capacity at Credit Suisse. Michael joined Credit Suisse in 2000 when the bank merged with Donaldson, Lufkin & Jenrette, where he was a member of the High Yield Capital Markets group. Prior to that, Michael worked at J.P. Morgan and Lehman Brothers, respectively, in their Emerging Markets groups.

Michael graduated from the Massachusetts Institute of Technology with a Bachelor of Science in Management from the Sloan School of Management. Michael is Chairman of the Board of Directors for HealthCare Chaplaincy Network, Inc., a leader in the research, education, and practice of spirituality within health care and palliative care, as well as . He also serves on the Board of Trustees of BioNJ, the life sciences trade association for New Jersey. Michael grew up in Ohio and has long been a supporter of The Ohio State University's James Cancer Center through Pelotonia, a cancer fundraising ride. In 2023 he was awarded the Pelotonia Legacy Award, in part for raising over $1.1M over the past fourteen years to support cancer research.

Geoff Kim

MD, Board Director

Co-Founder, CEO of Pi Health

Dr. Geoffrey Kim is the co-founder and Chief Executive Officer of Pi Health, a healthcare technology company launched in 2021 whose mission is to drive innovation to enable patients all over the world to have equal access to the highest quality of care and research. He has over 25 years of experience in oncology drug development, regulation, and precision medicine.

As Vice President of Applied Innovation at BeiGene, Geoff established an innovative team focused on increasing patient access to clinical trials and novel cancer therapies. His group pioneered methodologies to integrate diverse datasets and drive pipeline advancement through data analysis and strategic development, while simultaneously laying the groundwork for the establishment of Pi Health through the invention of the FICS technology platform.

Prior to his role at BeiGene, Geoff served as Vice President of Oncology Regulatory Science and Strategy at AstraZeneca. He led the regulatory function and shaped regulatory strategies for oncology treatments in a complex, evolving landscape, leading to the approvals of acalabrutinib in CLL and trastuzumab-deruxtecan in metastatic breast cancer. Previously, as Vice President of Strategic Combinations, he defined development and commercialization approaches for immuno-oncology combinations, external partnerships, and women’s cancers, including the strategic oversight of IO-based combination such as the combination of durvalumab and olaparib in multiple solid tumors.

Earlier in his career, Geoff played a pivotal role in oncology regulation at the U.S. Food and Drug Administration (FDA). As Deputy Director of the Oncology Center of Excellence, he helped launched the OCE under the provisions of the 21st Century Cures Act and laid the framework for the unified review of drugs, devices, and biologics that are intended to cure, treat, and prevent cancer. Geoff was also director of the Division of Oncology Products 1 in the Office of Hematology Oncology Products, where he oversaw the evaluation and regulation of oncology drug products for breast, genitourinary and gynecologic cancers and approved practice changing medicines such as CDK4/6 inhibitors for breast cancers, PARP inhibitors for ovarian cancers, and immunotherapy for genitourinary malignancies. He was also involved with numerous cross-functional working groups, developing policies pertaining to in-vitro companion diagnostics, combination products, and therapy dose optimization strategies for cancer medicines.

Dr. Kim completed his medical oncology fellowship at the National Cancer Institute (NCI) where he was active in both laboratory and clinical research in molecular signaling and ovarian cancer. He received his medical degree from New York Medical College and completed his residency in internal medicine at the Montefiore Medical Center.

Bobby Reddy

MD, Board Director

Co-Founder, CEO of Pi Health

Dr. Bobby Reddy, MD is the Chief Operating Officer and Co-Founder of Pi Health. At Pi Health, he leads global operations, business development, and commercial activities with the mission of driving equal access to innovative medicines and clinical trials for patients around the world. Previously, he served in leadership positions at BeiGene and AstraZeneca. At BeiGene, he was Executive Director of Applied Innovation, a technology incubator in the Office of the CEO, which developed novel technologies to improve R&D and commercial capabilities. In this role, Dr. Reddy was the co-inventor of multiple patented technology applications which have successfully undergone enterprise adoption. He also built and managed multidisciplinary, global teams who led strategy, business development, global operations, and legal activities to drive development, implementation and growth of incubated technologies and companies. At AstraZeneca, Dr. Reddy was Head of Oncology Regulatory Science and Innovation, where he was a member of the global Oncology Regulatory Science and Strategy leadership team.

Previous to his roles in pharma and biotech, Dr. Reddy was faculty of Harvard Medical School and a physician scientist and clinical dermatologist at Massachusetts General Hospital. His research focused on investigating the role of genetic and immunologic factors in melanoma development and progression, along with the development of novel therapeutic strategies. He is also an alumnus of the Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program, through which he conducted research at the National Cancer Institute. He completed an Internal Medicine internship at Brigham and Women’s Hospital, during which he was given the Dunne Award for Humanism in Medicine by Harvard Medical School. He subsequently completed a Dermatology residency at Columbia University Medical Center, where he served as a Chief Resident during his final year of training. After residency, he completed a Melanoma Fellowship at Massachusetts General Hospital/Harvard Medical School. He obtained his M.D. with Alpha Omega Alpha honors from Rutgers–New Jersey Medical School. Dr. Reddy is a board-certified dermatologist and maintains an active clinical practice caring for patients at Massachusetts General Hospital, where he also teaches and mentors medical students and trainees.

Kevin Ryan

Board Advisor

Founder & CEO, AlleyCorp

Often called the “Godfather of NYC tech,” Kevin Ryan is one of the leading internet entrepreneurs and investors in New York. He is a co-founder of MongoDB, Business Insider, Gilt Groupe, Zola, Nomad Health, Pearl Health, and Transcend Therapeutics, and founds and actively invests in new companies with AlleyCorp every year. Kevin currently serves on 10 company boards.

Earlier in his career, Kevin helped to grow DoubleClick first as President and then as CEO, leading their growth from a 20-person startup to a publicly-traded global leader with over 1,500 employees, through IPO in 1998, and acquisition by Google in 2007.

Kevin has been a civic leader in New York at the city and state level. Appointed by Governor Cuomo, he served on a three-member Fast Food Wage Board that successfully advocated for a wage increase for the state’s fast food workers. Kevin was also a member of the state’s Backend Expenses Commission, advising on spending and enhancing efficiencies, as well as the MTA commission focused on engaging startups and new technologies to improve accessibility and congestion challenges in New York. Additionally, Kevin served on the board of the Trust for Governors Island.

Kevin serves on the Board of Tech:NYC, where he is a founding member and chairs the Policy Committee. He is also the Vice Chairman of The Partnership for New York City, a Director Emeritus at Human Rights Watch, and a member of the Council on Foreign Relations. Previously, Kevin held positions on the boards of Yale University, Yale University Press, INSEAD, Mercy Corps, The NYC Investment Fund, the advisory board of Doctors Without Borders, and the Yale International Council.

Actively engaged in philanthropy, Kevin and his wife Pascaline Servan-Schreiber support organizations including University of the People, The Marshall Project, MLT, Endeavor, Fund for Public Health in NYC, and the Center for Mindful Learning. He continues to be one of the leading funders of the Yale Program for Psychedelic Science. AlleyCorp also invests out of a dedicated Social Impact vertical, which funds both for-profit companies and nonprofit entities dedicated to building technology solutions for low-income and underserved families.

Kevin has been recognized as Entrepreneur of the Year by Ernst & Young, LLP, featured as one of The 100 Most Influential New Yorkers of the Past 25 Years by The Observer, and named one of the 50 Most Influential Business People by Crain’s New York Business, where he was later inducted into the Hall of Fame.